Everything below concerns Angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
=== KwaZulu Bantustan === KwaZulu was a bantustan in South Africa, intended by the apartheid government as a semi-independent homeland for the Zulu people. The capital was moved from Nongoma to Ulundi in 1980. It was led until its abolition in 1994 by Chief Mangosuthu Buthelezi of the Zulu royal family and head of the Inkatha Freedom Party (IFP). It was merged with the surrounding South African province of Natal to form the new province of KwaZulu-Natal. The name KwaZulu translates roughly as Place of Zulus, or more formally Zululand.
In the United States, it is recommend to fix homes with radon levels at or above 4 pCi/L. At the same time it is also recommends that people think about fixing their homes for radon levels between 2 pCi/L and 4 pCi/L. In the United Kingdom the ideal is presence of radon indoors is 100 Bq/m-3. Action needs to be taken in homes with 200 Bq/m−3 or more. Interactive maps of radon affected areas are available for various regions and countries of the world.
Adedapo Segun (North West) Bello Rabiu (North West) Yusuf Usman (North East) Babs Omotowa (North Central), former Managing Director of Nigeria Liquefied Natural Gas Austin Avuru (South-South), Non-Executive Director David Ige (South-West) Henry Obih (South-East) Lydia Jafiya, Permanent Secretary of the Federal Ministry of Finance (Ministry’s representative) Aminu Ahmed (Ministry of Petroleum Resources representative) The Group Chief Executive Officer, Bayo Ojulari, has since resumed his duties and represented NNPCL at various official events, including an empowerment program for National Youth Service Corps (NYSC) members.
=== LGR4 === LGR4 binds R-spondins to activate the Wnt signaling pathway. Wnt signaling regulates bone mass and osteoblast differentiation and is important for the development of bone, heart, and muscle. An LGR4 nonsense mutation in a healthy population has been linked to low bone mass density and symptoms of osteoporosis. LGR4 mutant mice showed the observed low bone mass is not due to age-related bone loss. Mutations in LGR4 have been associated with family lineages with medical histories of rare bone disorders. Wild-type mice lacking LGR4 also displayed delayed osteoblast differentiation during development, showcasing the important role of LGR4 in bone mass regulation and development.
Sources: en.wikipedia.org
== Distribution and habitat == Panaeolus cyanescens is a coprophilous (dung-inhabiting) species which occurs in both the Neotropics and Paleotropics. It has been found in Vietnam, Africa (including South Africa, Mauritius, Madagascar and Democratic Republic of the Congo), Australia, Belize, the Caribbean (Bermuda, Grenada, Barbados Jamaica, Trinidad, and Puerto Rico), Costa Rica, India, Malaysia, Indonesia, Sri Lanka, Cambodia, Thailand, Japan, Mexico, Oceania (Fiji and Samoa), the Philippines, South America (Bolivia, Brazil, Paraguay, Colombia, Venezuela, and Ecuador), South Korea, and the United States (California, Hawaii, Louisiana, Mississippi, Alabama, Florida, Tennessee, Texas, Kentucky, Virginia, Georgia, and North Carolina).
== Aftermath == After returning to France in August 1804, Alexander von Humboldt and Aimé Bonpland arrived in Bordeaux after a swift Atlantic crossing. Their return after six years abroad was marked by the need to adjust to changed circumstances and reintegrate into European life. During quarantine, Humboldt wrote to the Institut National in Paris, informing them of his safe arrival. This news caused surprise, as rumors of his death had circulated in Europe. Humboldt reached Paris in late August, looking healthy and energetic. He was warmly welcomed by friends and family, with accounts noting he appeared unchanged by his long absence. Parisian society celebrated Humboldt as a hero. He was honored at scientific meetings and social gatherings, gaining widespread public attention for his South American explorations. His collections and drawings, exhibited at the Jardin des Plantes, attracted large crowds. Within six weeks, the Institut National held a special meeting where Humboldt presented his scientific results, receiving enthusiastic applause. In mid-October, Humboldt presented the first reports of his journey at a meeting of the Institut National des Sciences et Arts, a French government organisation created in 1795 to promote science, the beaux arts, and literature. The meeting was crowded and highly anticipated. In October of that year, the inaugural exhibition of Humboldt's botanical collection was inaugurated at the Jardin des Plantes, where it met with considerable acclaim.
Additional measures may include extracorporeal shockwave therapy or surgery. Between 4% and 7% of people have heel pain at any given time: about 80% are due to plantar fasciitis. Approximately 10% have the disorder at some point. It becomes more common with age. It is unclear whether one sex is more affected than the other.
== The lesion == People with MMF-the-syndrome generally have a muscle biopsy consistent with MMF-the-lesion. Seen within the muscle are sheets of macrophage infiltration that stain positive with periodic acid–Schiff stain. Aluminum has been detected in these samples by energy-dispersive X-ray spectroscopy. The individuals had a history of receiving aluminium-containing vaccines, administered months to several years prior to observation of MMF lesion. A hypothetical interpretation of the biopsy finding is that the macrophages are stuck in a "death loop": MP ingests the aluminum, the aluminum causes lysosome rupture, the MP dies, and a newly arrived MP ingests the dead MP (along with the aluminum within) to repeat the loop.
While the Commission has a monopoly on initiating legislation, the European Parliament and the Council of the European Union have powers of amendment and veto during the legislative process. According to the Treaty on European Union articles 9 and 10, the EU observes "the principle of equality of its citizens" and is meant to be founded on "representative democracy". In practice, equality and democracy are still in development because the elected representatives in the Parliament cannot initiate legislation against the commission's wishes, citizens of smallest countries have greater voting weight in Parliament than citizens of the largest countries, and "qualified majorities" or consensus of the council are required to legislate. This "democratic deficit" has encouraged numerous proposals for reform, and is usually perceived as a hangover from earlier days of integration led by member states. Over time, the Parliament gradually assumed more voice: from being an unelected assembly, to its first direct elections in 1979, to having increasingly more rights in the legislative process. Citizens' rights are therefore limited compared to the democratic polities within all European member states: under TEU article 11, citizens and associations have the right to publicise their views and the right to submit an initiative that must be considered by the Commission if it has received at least one million signatures. TFEU article 227 contains a further right for citizens to petition the Parliament on issues which affect them.
Sources: en.wikipedia.org
=== Non-human primates === In spider monkeys, the clitoris is especially developed and has an interior passage, or urethra, that makes it almost identical to the penis, and it retains and distributes urine droplets as the female spider monkey moves around. Scholar Alan F. Dixson stated that this urine "is voided at the bases of the clitoris, flows down the shallow groove on its perineal surface, and is held by the skin folds on each side of the groove". Because spider monkeys of South America have pendulous and erectile clitorises long enough to be mistaken for a penis, researchers and observers of the species look for a scrotum to determine the animal's sex; a similar approach is to identify scent-marking glands that may also be present on the clitoris. The clitoris erects in squirrel monkeys during dominance displays, which indirectly influences the squirrel monkeys' reproductive success. The clitoris of bonobos is larger and more externalized than in most mammals; Natalie Angier said that a young adolescent "female bonobo is maybe half the weight of a human teenager, but her clitoris is three times bigger than the human equivalent, and visible enough to waggle unmistakably as she walks". Female bonobos often engage in the practice of genital-genital (GG) rubbing.
=== Cancer === PAHs have been linked to skin, lung, bladder, liver, and stomach cancers in well-established animal model studies. Specific compounds classified by various agencies as possible or probable human carcinogens are identified in the section "Regulation and Oversight" below.
(1881), classical scholar and educator Richard James Horatio Gottheil (1881), Zionist scholar, founder of the first Jewish fraternity Zeta Beta Tau Harry Thurston Peck (1881), literary critic and editor of The Bookman A. V. Williams Jackson (1883), specialist on Indo-European languages Charles Knapp (1887), classical scholar Frank Moore Colby (1888), historian and editor of The New International Encyclopedia Charles Sears Baldwin (1888), scholar and professor of rhetoric at Yale University John Dyneley Prince (1888), linguist; U.S. ambassador to Yugoslavia George Louis Beer (1892), renowned historian of the "Imperial school" Benjamin Lord Buckley (1892), educator, founder and headmaster of Buckley School Judah A. Joffe (1893), Yiddish philologist William Robert Shepherd (1893), cartographer, historian John Driscoll Fitz-Gerald (1895), Hispanic scholar Joel Elias Spingarn (1895), professor of comparative literature Mortimer Lamson Earle (1896), classical scholar Alfred L. Kroeber (1896), pioneering cultural anthropologist William Popper (1896), Orientalist and professor Frederick Paul Keppel (1898), educator, former president of the Carnegie Corporation of New York Frank Sutliff Hackett (1899), educator, founder of Riverdale Country School John Erskine (1900), Great Books pioneer Alexander Goldenweiser (1902), Russian-born anthropologist and sociologist Emanuel Goldenweiser (1903), economist and president of the American Economic Association Robert Livingston Schuyler (1903), scholar on American history, president of the American Historical Association Carlton J. H.
MedPlus was founded in 2006 by Madhukar Gangadi. The company's first store was launched in Hyderabad. Initially operating under the Aushadhi brand name, it was rebranded as MedPlus after the opening of the first 48 stores. The company opened pharmacies in the western states of Gujarat and Rajasthan in 2007 but had to shut down and exit operations due to recurring losses. It relaunched stores in Ahmedabad, Gujarat in 2014. In 2008, it opened diagnostics centers in five cities under its subsidiary MedPlus Pathlabs. In 2015, it started its e-pharmacy division. In December 2021, MedPlus Health Services launched its initial public offering (IPO) and got listed on the Indian stock exchanges.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.